The National Medical Products Administration (NMPA) of China has officially approved the New Drug Application (NDA) for Ecnoglutide Injection (Brand Name: Xianyida®), developed by Sciwind Biosciences Co., Ltd. ("Sciwind").
As the long-term strategic intellectual property partner of Sciwind, T&C is proud to have spearheaded the comprehensive global patent layout and protection strategy for this breakthrough therapy, ensuring a robust IP barrier for its successful commercialization.
A Global First in Metabolic Disease Treatment
Ecnoglutide marks a historic achievement as the world’s first approved cAMP-biased GLP-1 receptor agonist for blood glucose control in adults with type 2 diabetes. Its unique mechanism of action offers a next-generation therapeutic option, signaling a major leap forward in the treatment of metabolic diseases.
Strategic IP Navigation for Global Markets
Caihe Law Firm has been instrumental in transforming Sciwind’s scientific innovation into a formidable global asset portfolio.
Global Footprint: We facilitated 3 PCT international applications covering over 10 major pharmaceutical markets. This has resulted in a family of 30+ patents, with grants already secured in the United States, Japan, Europe, Canada, and Australia.
Precision Prosecution: Leveraging deep technical expertise in GLP-1 analogues, our team accurately defined the scope of protection for molecular structures, manufacturing processes, and formulations. We successfully navigated complex examinations across multiple jurisdictions to ensure the stability and exclusivity of the core technology.
Full-Lifecycle Protection: From initial patent mining and clinical-stage maintenance to pre-market risk mitigation (FTO), Caihe provided a "R&D-to-Market" service chain that shields the "first-in-class" attributes of Ecnoglutide from infringement and competition.
Empowering the Future of Biopharma
The launch of Xianyida® underscores Sciwind’s position as a leader in metabolic innovation. It also reaffirms Caihe Law Firm’s specialized capability in the biopharmaceutical sector.
"Our 'Technology + Law + Market' trinity model is designed to help innovative drug developers navigate the world's most rigorous IP environments," said a spokesperson for Caihe Law Firm. "We are committed to empowering more biotechs to scale globally with ironclad IP protections."
About T&C
T&C is a premier IP firm specializing in the life sciences and biotechnology sectors. With a track record of serving hundreds of pharmaceutical enterprises, we provide sophisticated legal solutions for patent prosecution, litigation, and international portfolio management.
